{Reference Type}: Journal Article
{Title}: Morphological characteristics of the foveal avascular zone in pathological myopia and its relationship with macular structure and microcirculation.
{Author}: Sui J;Li H;Bai Y;He Q;Sun Z;Wei R;
{Journal}: Graefes Arch Clin Exp Ophthalmol
{Volume}: 262
{Issue}: 7
{Year}: 2024 Jul 17
{Factor}: 3.535
{DOI}: 10.1007/s00417-024-06403-2
{Abstract}: OBJECTIVE: To explore the characteristics of macular structure, microcirculation, and foveal avascular zone (FAZ) morphology in pathological myopia and to research the associations between these factors and pathological myopia.
METHODS: This is a cross-sectional study. The study included 103 eyes with non-high myopia and 206 eyes with high myopia (139 with simple high myopia and 67 with pathological myopia). Macular structural and microcirculation parameters were determined using optical coherence tomography angiography (OCTA). The FAZ morphological parameters were measured manually using Image J software. Correlations between pathological myopia and various factors were analyzed.
RESULTS: Patients with pathological myopia had a thinner retinal thickness (RT) and choroidal thickness (CT) and a lower retinal superficial vascular density (SVD), retinal deep vascular complex density (DVD), choriocapillaris perfusion area (CCPA), and choroidal vascularity index (CVI) (all P < 0.05). Patients with pathological myopia had a larger FAZ area, perimeter, major axis, minor axis, acircularity index (AI), and lower circularity index (CI) (all P < 0.01). The axial length (AL), the major axis of the superficial FAZ, CI, and AI were significantly correlated with myopia severity (all P < 0.05).
CONCLUSIONS: Patients with pathological myopia exhibited worse macular microcirculation and thinner macular retina and choroid. The FAZ in pathological myopia was larger and more irregular. The AL, CI, and AI were significantly associated with myopia severity. Thus, CI and AI might serve as new indicators for monitoring the progression of myopia. Further investigations should be performed.
BACKGROUND: Clinical Trials.gov Identifier: ChiCTR2100046590.